期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HER2突变非小细胞肺癌患者的临床特征和疗效 被引量：2

The Clinical Characteristics and Efficacy of Non-Small Cell Lung Cancer Patients with HER2 Mutation
下载PDF
导出
摘要 1文献来源 Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation ： Epidemiologic characteristics and therapeutic perspectives [ J ]. J Clin Oncol, 2013,31 （16） ： 1997- 2003.
作者 赵明芳 刘云鹏 邓伟
机构地区 中国医科大学附属第一医院肿瘤内科 广东省人民医院肿瘤中心
出处 《循证医学》 CSCD 2014年第1期48-51,共4页 The Journal of Evidence-Based Medicine
关键词 非小细胞肺癌 HER2 突变 靶向治疗 流行病学 non-small cell lung cancer human epidermalgrowth factor 2 nmtation targeted therapy epidemiology
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor2-positive breast cancer [J]. J Clin Oncol, 2009,27 (34) : 5838-5847.
  • 2Perera SA, Li D, Shimamura T, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy [J]. Proe Natl Acad Sei USA, 2009,106(2):474-479.
  • 3Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas[J]. Clin Cancer Res, 2012,18(18) :4910-4918.
  • 4Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas [J]. Cancer Res, 2005,65(5) : 1642-1646.
  • 5Tomizawa K, Suda K, Onozato R, et al. Prognostieand predictive implications of HER2/ERBB2/neu gene mutations in lung caneers[J]. Lung Cancer, 2011,74( 1 ) : 139-144.
  • 6Stephens P, Hunter C, Bignell G, et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours [J]. Nature, 2004,431 (7008) : 525-526.
  • 7Li C, Sun Y, Fang R, et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains [J]. J Thorac Oncol, 2012,7( 1 ) : 85-89.
  • 8Gatzemeier U, Groth G, Butts C, et al. Randomized phase Ⅱ trial of Gemcitabine-Cisplatin with or without Trastuzumab in HER2-positive non-small cell lung cancer [J]. Ann Oncol, 2004,15(1) : 19-27.
  • 9Feng XL, Li L, Gao YN, et al. Overexpression of c-erbB-2 and loss of p16 have molecular diagnostic relevance but no prognostic value in lung cancer[ J ]. Med Oncol, 2011,28 (1): 336-341.
  • 10Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: A meta-analysis of published data[J]. J Thorac Oncol, 2010, 5(12) : 1922-1932.

同被引文献3

引证文献2

二级引证文献5

循证医学
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部